Search Results

Mosaic ImmunoEngineering, Inc. announced the signing of a license agreement with Case Western Reserve University for patented technology discovered at Case Western Reserve University and Dartmouth College.

PharmaTher Holdings Ltd. is pleased to announce that the Company has entered into an evaluation and exclusive option agreement with Case Western Reserve University in the development and commercialization for the intellectual property of ketamine in the treatment Rett Syndrome, a rare genetic neurological disorder.

SCYNEXIS, Inc. today announced that researchers from Case Western Reserve University in Cleveland have been awarded a competitive research grant of more than $3 million by the National Institutes of Health (NIH), to investigate a second generation fungerp (SCY-247).

Evergreen Nephrology is pleased to announce a new partnership with Western Kentucky Kidney Specialists.

NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF), is pleased to announce the University of Cincinnati and Case Western Reserve University (CWRU) have published a pioneering preclinical study in the peer-reviewed scientific journal Cell Reports demonstrating that NervGen’s proprietary drug, NVG-291-R.

Forge Biologics and Case Western Reserve University Announce Gene Therapy Workforce Development Partnership

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) today announced that investigators at the Louis Stokes Cleveland Veterans Affairs Medical Center, led by Katarina B. Greer, M.D.,M.S., Associate Professor of Medicine at Case Western Reserve University School of Medicine, have released data from a Department of Defense funded prospective clinical validation study of patients who met strict national society guideline criteria for esophageal precancer testing.